



MORBIDITY AND MORTALITY WEEKLY REPORT

- 325 Self-Reported Frequent Mental Distress Among Adults — United States, 1993–1996
- 331 Silicosis Deaths Among Young Adults — United States, 1968–1994
- 335 Publication of Surgeon General's Report on Smoking and Health
- 343 National Melanoma/Skin Cancer Detection and Prevention Month — May 1998

Self-Reported Frequent Mental Distress Among Adults — United States, 1993–1996

In the United States, an estimated 10% of persons have some recent disability from a diagnosable mental illness (e.g., schizophrenia, phobias, depression, and anxiety disorders), and up to 24% of adults have experienced a mental disorder during the preceding year (1,2). In 1997, the estimated cost of mental illness exceeded \$150 billion for treatment, social services, disability payments, lost productivity, and premature mortality (1). However, information is limited about the overall prevalence of general mental distress, which can be associated with the incidence and prevalence of specific mental illnesses and conditions (3). This report describes differences in the prevalence of self-reported frequent mental distress (FMD) for noninstitutionalized adults in the United States for specific demographic groups and by state and age-sex group using data from the Behavioral Risk Factor Surveillance System (BRFSS) for 1993–1996. The findings indicate high prevalences of FMD among persons who are unemployed or unable to work, indicated a "separated" or "widowed" marital status, or had annual household incomes of <\$15,000.

The BRFSS is an ongoing, state-based, random-digit-dialed telephone survey of the noninstitutionalized U.S. population aged ≥18 years that tracks the prevalence of key health- and safety-related behaviors and characteristics. Since January 1993, the interviews have included four health-related quality-of-life (HRQOL) questions (4), including the following general mental health question: "Now thinking about your mental health, which includes stress, depression and problems with emotions, for how many days during the past 30 days was your mental health not good?" Persons who reported that their mental health was not good for ≥14 of the preceding 30 days were defined as having FMD. This 14-day minimum period was selected because a similar period is often used by clinicians and clinical researchers as a marker for clinical depression and anxiety disorders, and a longer duration of reported symptoms is associated with a higher level of activity limitation (5). To permit comparisons, data were statistically weighted to reflect the age, race/ethnicity, and sex distribution of the state population and, when appropriate, age-standardized to the 1990 U.S. population aged ≥18 years using SUDAAN® (Software for the Statistical Analysis of Correlated Data).

Persons who reported ≥14 days of recent mental health problems had a comparatively high level of disability (i.e., they reported that poor physical or mental health had prevented them from performing their usual activities an average of 7.7 of the previous 30 days). In comparison, respondents with ≤2 recent days of mental distress reported having 0.9 recent days when illness restricted their usual activities.

During 1993–1996, the overall state-weighted prevalence of adults with FMD was 8.6% (Table 1). Of the demographic groups studied, the FMD prevalence was highest among persons who reported being unable to work (33.2%), indicated a "separated" marital status (18.5%), had annual household incomes of <\$15,000 (15.5%), had less than a high school (or equivalent) education (12.9%), were American Indians/Alaskan Natives (12.9%), or were aged 18–24 years (10.0%). Persons with the lowest FMD prevalence were those with annual household incomes of ≥\$50,000 (5.7%), college graduates (5.9%), aged 65–74 years (6.1%), Asians/Pacific Islanders (6.1%), employed for wages (6.7%), or married (7.3%). Women were more likely to report FMD (10.2%) than men (6.9%), and persons with no health insurance were more likely to report FMD (12.5%) than persons with insurance (8.0%).

The overall state-level prevalence of FMD among adults ranged from 4.9% in South Dakota to 12.8% in Kentucky. State-level FMD prevalences among men were highest

TABLE 1. Number of respondents to a question about mental health and percentage of those respondents who self-reported frequent mental distress (FMD),* by demographic characteristics — United States, Behavioral Risk Factor Surveillance System, 1993–1996

Characteristic	No. respondents	%	(SE†)	Characteristic	No. respondents	%	(SE†)
Sex				Education level	Тобронионе	,,,	(0_ /
Women	254,250	10.2	(0.1)	Less than high school			
Men	181,857	6.9	(0.1)	graduate	60,801	12.9	(0.3)
	101,037	0.5	(0.1)	High school graduate	143,542	9.0	(0.1)
Age group (yrs)	44 407	40.0	(0.0)	Some college or	140,042	5.0	(0.1)
18–24	41,197	10.0	(0.3)	technical school	118.529	8.6	(0.1)
25–34	90,678	8.7	(0.1)	College graduate	112,381	5.9	(0.1)
35–44	99,864	9.4	(0.1)		112,501	5.5	(0.1)
45–54	69,982	9.1	(0.2)	Employment status			
55–64	48,709	7.8	(0.2)	Employed for wages	231,815	6.7	(0.1)
65–74	51,473	6.1	(0.2)	Self-employed	37,698	7.0	(0.3)
≥75	34,204	6.5	(0.2)	Unemployed ≤1 year	9,593	14.7	(0.6)
Race/Ethnicity				Unemployed >1 year	6,985	17.8	(0.9)
White, non-Hispanic	358,755	8.3	(0.1)	Homemaker	35,648	9.4	(0.3)
Black, non-Hispanic	37,245	9.7	(0.2)	Student	15,145	9.6	(8.0)
Hispanic	23,127	10.3	(0.3)	Retired	82,786	11.9	(2.1)
Asian/Pacific Islander	9,228	6.1	(0.5)	Unable to work	12,903	33.2	(0.9)
American Indian/	0,220	• • •	(0.0)	Annual household			
Alaskan Native	4,667	12.9	(8.0)	income			
Other	2,292	10.7	(1.0)	<\$15.000	76,807	15.5	(0.2)
Marital status	, -			\$15,000-\$24,999	82.792	10.0	(0.2)
	240 520	7.0	(0.1)	\$25,000-\$49,999	136,984	7.2	(0.1)
Married	240,530	7.3	(0.1)	≥\$50,000	84,546	5.7	(0.2)
Divorced	53,653	13.4	(0.4)	· · ·	0 1,0 10	0.7	(0.2)
Widowed	47,055	15.9	(1.2)	Health insurance	000 000	0.0	(0.4)
Separated	11,266	18.5	(0.7)	Yes	382,600	8.0	(0.1)
Never married	74,291	9.3	(0.3)	No	52,457	12.5	(0.3)
Unmarried couple	8,574	12.0	(1.1)	Total	436,107	8.6	(0.1)

^{*} FMD applies to persons reporting ≥14 days of the preceding 30 days when their mental health was not good. Numbers in groups may not add to the overall sample size because persons for which values were missing were excluded from this analysis. Percentages in all groups except the age groups were age-adjusted to the 1990 U.S. population aged ≥18 years.

† Standard error.

in Colorado (13.1%) for persons aged 18–24 years and lowest in South Dakota for persons aged ≥65 years (2.6%) (Table 2).* State-level FMD prevalences among women were highest in New York (19.1%) for persons aged 18–24 years and lowest in Oklahoma for persons aged ≥65 years (3.3%).

During 1993–1996, overall FMD prevalence among men was highest among persons aged 18–24 years (7.8%) and lowest among persons aged ≥65 years (5.4%) (Table 2). Similarly, the overall FMD prevalence among women was highest among persons aged 18–24 years (12.3%) and lowest among persons aged ≥65 years (6.8%). The difference between FMD among women and among men was highest among persons aged 18–24 years and lowest among persons aged ≥65 years.

Reported by the following BRFSS coordinators: J Cook, MBA, Alabama; P Owen, Alaska; B Bender, MBA, Arizona; J Senner, PhD, Arkansas; B Davis, PhD, California; M Leff, MSPH, Colorado; M Adams, MPH, Connecticut; F Breukelman, Delaware; C Mitchell, District of Columbia; D McTague, MS, Florida; K Powell, MD, Georgia; A Onaka, PhD, Hawaii; J Aydelotte, Idaho; B Steiner, MS, Illinois; K Horvath, Indiana; A Wineski, Iowa; M Perry, Kansas; K Asher, Kentucky; R Jiles, PhD, Louisiana; D Maines, Maine; A Weinstein, MA, Maryland; D Brooks, MPH, Massachusetts; H McGee, MPH, Michigan; N Salem, PhD, Minnesota; D Johnson, Mississippi; T Murayi, PhD, Missouri; F Ramsey, Montana; S Huffman, Nebraska; E DeJan, MPH, Nevada; L Powers, MA, New Hampshire; G Boeselager, MS, New Jersey; W Honey, MPH, New Mexico; T Melnik, DrPH, New York; K Passaro, PhD, North Carolina; J Kaske, MPH, North Dakota; R Indian, MS, Ohio; N Hann, MPH, Oklahoma; J Grant-Worley, MS, Oregon; L Mann, Pennsylvania; J Hesser, PhD, Rhode Island; M Lane, MPH, South Carolina; M Gildemaster, South Dakota; D Ridings, Tennessee; K Condon, Texas; R Giles, Utah; C Roe, MS, Vermont; L Redman, MPH, Virginia; K Wynkoop-Simmons, PhD, Washington; F King, West Virginia; P Imm, MS, Wisconsin; M Futa, MA, Wyoming. E Borawski, G Wu, H Jia, Case Western Reserve Univ School of Medicine, Cleveland, Ohio. Survey and Analysis Br, Center for Mental Health Svcs, Substance Abuse and Mental Health Svcs Administration. Health Care and Aging Studies Br, Div of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Editorial Note: Perceived mental distress is a key component of HRQOL and is believed to be an important determinant of health behaviors related to chronic disease and disability prevention (4). Mental illness includes a broad range of emotional and psychological conditions ranging in severity from clinically diagnosed disorders requiring hospitalization and sometimes resulting in suicide to the more common and often undiagnosed affective conditions (2,6). Survey data about the prevalence of mental distress and mental illness have been difficult to obtain because of concerns about potential respondent objections to including mental health questions on a health survey and because earlier batteries of questions to evaluate mental health were too long to be easily added to a general population survey. Administrative data about the prevalence of mental illness are limited because only small proportions of adults with treatable conditions actually seek professional help; for example, only 34.2% of nonrural, noninstitutionalized persons aged 18-54 years with major depressive disorders sought help in 1992, and only 14.3% of adults with personal and emotional problems sought help in 1993 (2). The BRFSS data in this report, based on a 99% response rate to the one mental health question in the survey, indicate that respondents' objections to a question about mental health were minimal and identified differences in self-reported FMD between states and between age and sex groups in each state.

^{*}The District of Columbia was not included in state comparisons, but during 1993–1996 the prevalence of FMD for men aged 25–44 years and 45–64 years was lower than in any of the states.

TABLE 2. Frequent mental distress (FMD) among adults,* by state, age group, and sex — United States, Behavioral Risk Factor Surveillance System, 1993–1996

		18–2	4 yrs			25–4	4 yrs			45–6	4 yrs		≥65 yrs			
	М	len	Wo	men	M	en	Wo	men	М	en	Wo	men	IV	len	Wo	men
State	%	(SE [†])	%	(SE)	%	(SE)	%	(SE)	%	(SE)	%	(SE)	%	(SE)	%	(SE)
Alabama	8.8	(1.7)	8.2	(1.4)	6.1	(0.7)	9.8	(0.7)	7.2	(1.0)	9.6	(0.9)	6.3	(1.1)	7.1	(8.0)
Alaska	5.1	(2.0)	8.7	(2.3)	7.4	(0.9)	10.7	(1.0)	5.4	(1.0)	6.9	(1.2)	7.7	(2.8)	7.2	(2.4)
Arizona	5.9	(1.5)	9.9	(1.9)	8.0	(1.3)	9.8	(0.9)	6.5	(1.1)	10.9	(1.2)	4.9	(1.1)	6.4	(0.9)
Arkansas	4.7	(1.2)	9.3	(1.5)	6.1	(8.0)	10.9	(0.9)	6.5	(0.9)	10.3	(0.9)	6.3	(1.2)	8.3	(1.0)
California	9.1	(1.5)	13.6	(1.4)	7.6	(0.5)	12.3	(0.6)	8.7	(0.9)	10.4	(0.7)	5.1	(8.0)	6.6	(0.7)
Colorado	13.1	(2.2)	17.3	(2.3)	7.9	(0.7)	11.8	(8.0)	6.0	(0.9)	9.6	(0.9)	4.3	(1.1)	8.1	(1.1)
Connecticut	5.8	(1.6)	9.9	(1.7)	5.7	(0.7)	7.8	(0.6)	5.3	(8.0)	9.1	(1.0)	2.9	(8.0)	4.4	(8.0)
Delaware	5.8	(1.5)	13.5	(1.8)	7.5	(8.0)	11.9	(8.0)	6.9	(0.9)	12.3	(1.0)	4.3	(8.0)	6.8	(8.0)
District of Columbia	4.9	(1.8)	7.0	(2.0)	3.6	(0.8)	6.7	(0.9)	2.5	(8.0)	7.0	(1.3)	6.4	(1.9)	6.4	(1.5)
Florida	12.6	(1.7)	13.7	(1.5)	8.2	(0.6)	13.8	(0.7)	8.8	(8.0)	10.8	(0.7)	5.3	(0.6)	7.5	(0.6)
Georgia	6.8	(1.5)	8.0	(1.4)	6.4	(0.6)	8.6	(0.6)	6.2	(0.8)	8.0	(0.8)	7.0	(1.1)	6.7	(8.0)
Hawaii	7.7	(1.6)	8.4	(1.4)	6.3	(0.7)	8.8	(0.7)	5.0	(0.9)	8.0	(0.9)	3.4	(0.9)	4.7	(8.0)
Idaho	7.0	(1.4)	14.1	(1.9)	7.9	(0.9)	12.0	(0.8)	5.9	(0.9)	11.9	(1.1)	4.7	(0.9)	6.0	(8.0)
Illinois	6.5	(1.4)	10.3	(1.5)	4.3	(0.5)	8.5	(0.6)	5.7	(0.7)	8.5	(0.8)	5.3	(1.0)	5.3	(0.7)
Indiana	10.1	(1.7)	13.9	(1.8)	7.4	(0.7)	13.8	(0.8)	7.3	(0.9)	12.4	(1.0)	5.3	(1.0)	7.8	(0.8)
lowa	5.7	(1.0)	10.7	(1.4)	5.2	(0.5)	9.3	(0.6)	6.5	(0.8)	10.5	(0.8)	6.9	(0.9)	7.3	(0.7)
Kansas	6.1	(1.7)	10.9	(1.8)	5.9	(0.7)	8.8	(0.7)	5.8	(0.9)	8.4	(0.9)	4.4	(0.9)	4.7	(0.7)
Kentucky	7.9	(1.4)	14.9	(1.6)	9.4	(0.8)	16.5	(0.8)	11.8	(1.0)	18.0	(1.0)	8.0	(1.0)	11.4	(0.9)
Louisiana	6.2	(1.5)	11.8	(1.9)	7.5	(0.9)	12.3	(0.9)	6.8	(1.1)	11.5	(1.1)	5.0	(1.2)	5.9	(0.9)
Maine	4.2	(1.5)	9.1	(2.2)	6.3	(0.9)	8.3	(0.8)	7.1	(1.1)	8.2	(1.0)	5.5	(1.2)	4.9	(0.8)
Maryland	6.9	(1.1)	9.9	(1.1)	5.7	(0.4)	8.0	(0.4)	5.1	(0.5)	8.5	(0.6)	4.9	(0.7)	6.3	(0.7)
Massachusetts	8.8	(1.9)	14.7	(2.2)	9.4	(0.9)	13.0	(0.9)	7.6	(1.0)	11.4	(1.1)	4.0	(0.9)	8.2	(1.1)
Michigan	9.5	(1.7)	14.5	(1.7)	7.6	(0.7)	13.2	(0.8)	6.8	(0.8)	10.0	(0.8)	5.6	(1.1)	10.0	(1.0)
Minnesota	8.6	(1.2)	12.0	(1.3)	7.5	(0.5)	10.9	(0.5)	6.2	(0.6)	8.3	(0.6)	8.0	(0.9)	7.8	(0.7)
Mississippi	4.7	(1.3)	11.8	(2.0)	6.2	(0.8)	9.5	(0.8)	6.9	(1.0)	12.5	(1.1)	5.9	(1.3)	7.9	(1.0)
Missouri	6.0	(1.7)	11.1	(1.9)	8.2	(0.9)	12.3	(0.9)	6.1	(1.0)	12.2	(1.1)	8.0	(1.5)	6.8	(0.9)
Montana	3.5	(1.7)	9.6	(1.9)	6.6	(0.8)	9.6	(0.9)	6.7	(1.1)	9.4	(1.0)	3.5	(0.9)	4.5	(0.8)
Nebraska	6.7	(4.1)	8.9	(2.7)	6.6	(0.8)	9.7	(0.7)	5.5	(0.9)	8.9	(0.9)	5.6	(1.0)	5.5	(0.7)
Nevada	10.7	(1.9)	18.4	(2.1)	11.2	(1.0)	12.7	(0.9)	7.4	(1.1)	12.9	(1.2)	4.8	(1.2)	10.7	(1.6)
New Hampshire	8.8	(2.4)	11.2	(2.1)	7.2	(0.8)	10.6	(0.8)	5.1	(0.8)	9.2	(1.0)	4.4	(1.1)	6.9	(1.1)
New Jersey	5.1	(1.4)	8.4	(1.5)	5.3	(0.7)	9.4	(0.8)	6.3	(1.0)	7.3	(0.8)	6.4	(1.4)	6.9	(1.0)
New Mexico	7.1	(1.9)	8.8	(2.0)	6.0	(0.9)	11.4	(1.1)	5.6	(1.0)	9.4	(1.1)	4.1	(1.0)	6.3	(1.1)
New York	9.5	(1.5)	19.1	(2.6)	7.8	(0.6)	11.3	(0.6)	6.2	(0.7)	11.3	(0.9)	5.9	(1.0)	6.5	(0.8)
North Carolina	3.5	(0.9)	5.9	(1.1)	5.8	(0.6)	8.2	(0.6)	4.2	(0.6)	9.2	(0.8)	4.3	(0.8)	6.8	(0.8)

v ==																	
Total	7.8	(0.3)	12.3	(0.4)	7.1	(0.1)	11.1	(0.1)	6.9	(0.2)	10.0	(0.2)	5.4	(0.2)	6.8	(0.2)	~
Wyoming	8.7	(1.9)	7.5	(2.4)	7.4	(1.0)	10.9	(0.9)	6.6	(1.1)	9.1	(1.0)	4.0	(1.0)	5.8	(1.1)	<i>Jea</i>
Wisconsin	4.8	(1.4)	9.8	(1.9)	6.5	(0.7)	9.7	(8.0)	6.2	(1.0)	8.4	(1.0)	4.3	(1.1)	7.0	(1.1)	Ĕ.
West Virginia	5.9	(1.4)	7.6	(1.4)	6.6	(0.7)	11.5	(0.7)	10.0	(1.0)	11.0	(8.0)	5.4	(0.9)	7.6	(0.7)	ňt
Washington	9.0	(1.3)	15.0	(1.5)	7.2	(0.5)	12.2	(0.6)	6.5	(0.6)	9.7	(0.7)	3.9	(8.0)	5.7	(8.0)	Ç
Virginia	7.0	(1.4)	15.2	(2.1)	6.3	(0.7)	10.0	(0.7)	6.5	(1.0)	8.0	(0.9)	3.7	(1.1)	7.2	(1.1)	I
Vermont	6.5	(1.6)	8.6	(1.5)	7.5	(0.7)	12.0	(0.7)	6.5	(8.0)	10.5	(0.8)	3.8	(8.0)	5.5	(0.7)	S
Utah	7.9	(1.3)	11.3	(1.4)	7.0	(0.7)	12.3	(0.9)	6.1	(0.9)	10.1	(1.0)	4.9	(1.0)	6.2	(0.9)	ess
Texas	8.4	(1.9)	16.0	(2.2)	8.4	(0.9)	11.0	(0.8)	8.7	(1.1)	9.6	(1.0)	6.7	(1.6)	6.7	(1.1)	str
Tennessee	4.2	(1.0)	10.1	(1.5)	5.0	(0.5)	9.6	(0.6)	6.8	(8.0)	9.7	(0.7)	7.9	(1.2)	7.5	(0.8)	Dist
South Dakota	2.9	(8.0)	7.9	(1.4)	4.3	(0.6)	6.6	(0.7)	4.3	(0.7)	5.8	(8.0)	2.6	(0.6)	4.3	(0.7)	_
South Carolina	6.6	(1.4)	9.0	(1.4)	5.9	(0.7)	11.4	(8.0)	8.2	(1.1)	10.5	(0.9)	5.3	(1.2)	7.6	(1.0)	nta
Rhode Island	9.4	(2.3)	11.7	(2.0)	8.8	(0.9)	13.8	(1.0)	7.8	(1.1)	11.5	(1.2)	5.0	(1.1)	4.6	(0.9)	1ei
Pennsylvania	8.4	(1.4)	8.6	(1.3)	6.5	(0.5)	13.1	(0.9)	6.8	(0.7)	9.7	(0.7)	5.5	(8.0)	6.7	(0.7)	Š
Oregon	8.9	(1.4)	14.7	(1.6)	8.0	(0.6)	12.0	(0.7)	6.4	(0.7)	11.1	(0.8)	4.0	(0.7)	6.1	(0.7)	ž
Oklahoma	9.0	(2.0)	7.3	(1.9)	7.1	(1.0)	8.6	(0.8)	3.9	(8.0)	9.7	(1.0)	2.9	(0.7)	3.3	(0.5)	JU.
Ohio	4.4	(1.7)	8.7	(1.7)	6.9	(1.0)	8.9	(8.0)	5.7	(1.0)	9.3	(1.0)	3.7	(1.0)	5.1	(8.0)	pe)
North Dakota	3.7	(0.9)	13.7	(1.8)	6.1	(0.7)	12.0	(0.9)	8.3	(1.1)	9.9	(1.0)	4.6	(8.0)	7.4	(8.0)	Ţ

^{*} FMD applies to persons reporting ≥14 days of the preceding 30 days when their mental health was not good. Total sample size=436,107.
† Standard error.

The measure of recent mental health described in this report correlates strongly with other BRFSS HRQOL questions used by some states that specifically ask about days of recent depression and anxiety (4). The BRFSS measure also correlates well in a general population comparison with the widely used and clinically validated Medical Outcomes Study Short Form 36 (SF-36)[†] (7). In that comparison, the measure of recent mental health had acceptable validity and correlated most strongly with the related SF-36 scales, including its mental health, role emotional, and mental component summary scales. The BRFSS mental health measure has correlated acceptably (0.59) with the widely-used and clinically validated Center for Epidemiological Studies of Depression scale in a recent study of older, low-income black males (8). The finding of large but expected (6) differences in FMD across socioeconomic and demographic groups known to differ in their mental health characteristics further supports the construct validity of the measure in this study. Although these validation findings suggest that persons with FMD may have a high prevalence of diagnosable mental illness, the proportion cannot be estimated accurately without a population study that includes both the BRFSS measure and a clinical psychiatric examination.

This analysis has at least four limitations. First, the BRFSS underrepresents persons with FMD because it excludes homeless persons and persons in institutional settings (including hospitals, prisons, and group homes), who are known to have a very high prevalence of severe mental illness (9). Second, the BRFSS also may underrepresent persons with FMD because households without telephones (which generally have a higher percentage of high-risk persons) are excluded and because adequate respondent physical and mental functional capacity (which can be lacking for distressed persons) are needed to complete the survey. Third, observed state-specific FMD differences may reflect uncontrolled differences in population composition, socioeconomic conditions, climate, natural and human-made disasters, environmental quality, and other unknown factors. Finally, the BRFSS mental health measure was not validated for detection of mental illness with clinical psychiatric examinations.

Additional analyses of these data are planned to examine the relations between reported mental distress, activity limitation, and chronic health conditions, and the effects of mental distress on the adoption and maintenance of preventive health behaviors. The large amount of BRFSS data that state health agencies are collecting about recent mental health and related HRQOL items (>500,000 adults have been surveyed through 1997) gives public health planners a valuable resource of population data (4). This information can help set population health goals and objectives and help monitor the performance of health programs over time (10). The data reported here suggest that public health strategies are needed—particularly for younger adults, women, Hispanics, and American Indians/Alaskan Natives, and for persons who reported the loss of a marital partner, are not working, or have limited socioeconomic resources—to ensure that community health objectives associated with mental health can be met (e.g., increasing adult access to community mental health services and increasing the proportion of persons with clinically significant mental distress who obtain treatment).

[†]The SF-36 is a set of 36 survey questions and associated subscales designed to measure key aspects of HRQOL in patient and community populations.

References

- National Institute of Mental Health. Mental illness in America: the National Institute of Mental Health agenda. World-Wide Web site http://www.nimh.nih.gov/research/amer.htm. Accessed April 13, 1998.
- Substance Abuse and Mental Health Services Administration. Mental health, United States, 1996. Rockville, Maryland: US Department of Health and Human Services, Public Health Service, 1997.
- 3. Mrazek PJ, Haggerty RJ, eds. Reducing risks for mental disorders: frontiers for preventive intervention research. Washington, DC: National Academy Press, 1994.
- 4. CDC. Health-related quality of life and activity limitation—eight states, 1995. MMWR 1998; 47:134–40.
- Milazzo-Sayre LJ, Henderson MJ, Manderscheid RW. Serious and severe mental illness and work: what do we know? In: Bonnie RJ, Monahan J, eds. Mental disorder, work disability, and the law. Chicago, Illinois: University of Chicago Press, 1997.
- Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8–19.
- 7. Newschaffer CJ. Validation of BRFSS HRQOL measures in a statewide sample. Atlanta, Georgia: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, 1998.
- Albert SM. Validation of BRFSS QOL items: Harlem Prostate Screening Project (final report, project U48/CU209663). New York: Columbia University College of Physicians and Surgeons, 1997.
- 9. Substance Abuse and Mental Health Services Administration. Estimation methodology for adults with serious mental illness (SMI). Federal Register 1997:62;14928.
- 10. Durch J, Bailey LA, Stoto MA, eds. Improving health in the community: a role for performance monitoring. Washington, DC: National Academy Press, 1997.

Silicosis Deaths Among Young Adults — United States, 1968–1994

Silicosis is a potentially fatal and typically chronic fibrotic lung disease caused by occupational exposure to respirable crystalline silica dust (1). In the United States, most silicosis-associated deaths occur among persons aged ≥65 years (2), often following many years of silica dust exposure. However, the continuing occurrence of silicosis deaths in young adults reflects relatively recent overexposures, some of sufficient magnitude to cause severe disease and death after relatively short periods of exposure. This report describes deaths among two young adults with silicosis and underscores the risk for deaths from silicosis at relatively young ages.

Case Reports

Two sandblasters died from progressive massive fibrosis (PMF), an advanced form of silicosis, following intensive dust exposure during abrasive sandblasting of oil field pipes and tanks in western Texas (3). The first death occurred in a 36-year-old man who had worked as a sandblaster for 36 months from 1984 to 1988, when PMF was diagnosed. He died from respiratory failure in 1995, 11 years after his initial exposure. The second death occurred in a 30-year-old man who had worked as a sandblaster for 48 months during 1986–1990. He died from respiratory failure in 1996, 10 years after initial exposure.

At diagnosis, each worker had radiographic evidence of severe silicosis; one underwent a lung biopsy that revealed silicotic nodules and fibrosis. Autopsies for both


revealed grey and hard upper and middle lobes of the lungs, with multiple small nodules palpable in the lower lobes. Microscopic examination revealed widespread interstitial inflammation and fibrosis, and mineralogic analysis revealed extremely high silica particle content.

Mortality Surveillance Trends

Using CDC's National Center for Health Statistics (NCHS) multiple cause-of-death data files for all U.S. deaths from 1968 through 1994, presumptive silicosis deaths were identified using *International Classification of Diseases* (ICD) codes^{*} listed as either an underlying or contributing cause of death among persons aged ≥15 years. Descriptive analyses were conducted using three age groups (15–44 years, 45–64 years, and ≥65 years). Usual industry and occupation, coded in accordance with Bureau of Census industry and occupation codes, were examined in the NCHS data files.

During 1968–1994, a total of 14,824 silicosis-associated deaths were recorded; 11,250 (75.9%) occurred among persons aged ≥65 years, 3367 (22.7%) among persons aged 45–64 years, and 207 (1.4%) among persons aged 15–44 years. Overall, silicosis deaths declined substantially from 1157 in 1968 to <400 annually after 1980 (Figure 1). Among young persons (i.e., aged 15–44 years), deaths from silicosis declined less

FIGURE 1. Number of silicosis-associated deaths, by age group and year — United States, 1968–1994



^{*}The Eighth Revision (ICD-8) codes 010 and 515.0 were used for 1968–1978, and the Ninth Revision (ICD-9) code 502 was used for 1979–1994.


during 1968–1994 (Figure 1). Young silicosis decedents resided in 38 states and the District of Columbia (Figure 2); 17 (8.2%) were aged 15–24 years; 40 (19.3%), aged 25–34 years; and 150 (72.5%), aged 35–44 years.

Among young silicosis decedents, 57.0% were white, and 90.8% were male. Among silicosis decedents aged ≥65 years, 90.0% were white, and 98.1% were male. The proportion of decedents of races other than white generally increased during 1968–1994 in both the 45–64 and ≥65 age groups, but remained relatively stable among young decedents. In all three age groups, the proportion of female decedents generally increased. Of the nine silicosis deaths that occurred among young women during 1985–1994, six were of races other than white.

Reporting to NCHS of the "usual" industry and occupation of decedents began in 1985, with varying numbers of states (range: 16–22 states) providing this information in that and subsequent years (Figure 2). Of the 59 young silicosis decedents during 1985–1994, a total of 25 (42.4%) died in a year for which their state of residence provided decedents' employment information to NCHS. Construction and manufacturing were coded most frequently as the usual industry (28.0% each); no deaths were attributed to mining. In comparison, among 897 silicosis decedents aged ≥65 years, manufacturing accounted for 46.2%, mining for 21.1%, and construction for 9.5% of deaths. Usual occupations for the 25 young silicosis decedents included operators of various machines used to crush, grind, mix, and blend materials (six [24.0%]); painters/paint spray operators (five [20.0%]); construction trades (four [16.0%]); and laborers, except construction (four [16.0%]).

Reported by: Div of Respiratory Disease Studies, National Institute for Occupational Safety and Health; and an EIS officer, CDC.

FIGURE 2. Number of silicosis-associated deaths among persons aged 15–44 years, by state, and frequency of provision of usual employment data by states — United States, 1985–1995



Editorial Note: Primary prevention of silicosis through exposure control is important because no effective medical treatment exists for this disease, which continues to progress even after a worker is removed from further exposure (4). Despite the existence of legally enforceable limits on worker exposure to respirable crystalline silica dust, overexposures of sufficient magnitude to cause premature deaths continue to occur in the United States. Silicosis latency and rate of progression correlate with intensity of exposure (5); extremely high exposures are associated with much shorter latency and more rapid disease progression. Consequently, silicosis-associated deaths in young persons generally result from more recent and intense exposure to silica dust.

The sex, racial, and employment differences between young and older silicosis decedents presented in this report may reflect changes in both workforce demographics and industrial activity over recent decades, especially given the increasing proportion of females among young silicosis decedents. The high, but temporally constant, proportion of minorities among young silicosis decedents may reflect the generally higher levels of dust to which minority workers have been exposed (6,7). For example, in the foundry industry, higher levels of silica dust exposure accounted for apparently higher risk for silicosis among black workers than among white workers (7).

Extreme overexposures to respirable silica have been documented during sand-blasting (5) and in the construction industry (8). Abrasive blasting with silica sand, often used to prepare surfaces for painting, has been associated with exposures up to 200 times the CDC's National Institute for Occupational Safety and Health (NIOSH)-recommended exposure limit for respirable crystalline silica dust (0.05 mg/m³) (5). NIOSH has recommended that silica sand be prohibited as an abrasive blasting agent (5).

The findings in this report are subject to several limitations. The ICD code used to identify presumptive silicosis is not entirely specific for silicosis, and cause-of-death coding errors can occur. However, a review of a sample of death certificates of 10 young decedents in whom silicosis was presumptively diagnosed found that only two were not attributable to silicosis. In addition, many states do not provide decedents' employment data to NCHS, and the Census employment codes lack substantial detail. Even when recorded accurately and coded appropriately, silicosis decedents' usual employment does not always represent employment relevant to silica exposure. Finally, the NCHS data lack personal identifiers necessary for follow-back to confirm silicosis as cause of death, to ascertain details about occupational exposure to silica dust, and to investigate specific workplaces for potential ongoing hazardous exposure.

The Sentinel Event Notification System for Occupational Risks (SENSOR) program^T and a preexisting surveillance program in New Jersey have demonstrated that identifying silicosis deaths from state mortality data files is one of several useful case-ascertainment methods for state-based silicosis surveillance and related preventive intervention (9). Although implementation of all silicosis case ascertainment methods and case follow-up activities field-tested through SENSOR may be optimal, state health departments often do not have sufficient resources for a comprehensive approach.

[†] The SENSOR program, involving cooperative agreements between NIOSH and state health departments, is designed to develop and field test surveillance and intervention strategies for selected occupational conditions.

In 1997, the Council of State and Territorial Epidemiologists adopted a resolution recommending that silicosis be made a reportable condition. Regardless of reporting requirement status, state health departments can initiate active efforts in silicosis prevention by identifying silicosis deaths through annual review of state mortality data and giving priority to investigation of circumstances surrounding those that occur at younger ages. Additional information about silicosis prevention activities and technical assistance for worksite investigations and other follow-back activities are available from NIOSH, telephone (304) 285-6115.

References

- 1. American Thoracic Society. Adverse effects of crystalline silica exposure. Am J Respir Crit Care Med 1997;155:761–5.
- National Institute for Occupational Safety and Health. Work-related lung disease surveillance report 1996. Cincinnati, Ohio: US Department of Health and Human Services, Public Health Service, CDC, 1996; DHHS publication no. (NIOSH)96-134.
- 3. Abraham JL, Wiesenfeld SL. Two cases of fatal PMF in an ongoing epidemic of accelerated silicosis in oilfield sandblasters: lung pathology and mineralogy. Ann Occup Hyg 1997; 41(suppl 1):440–7.
- 4. Kreiss K, Zhen B. Risk of silicosis in a Colorado mining community. Am J Ind Med 1996;30: 529–39.
- 5. National Institute for Occupational Safety and Health. Alert: request for assistance in preventing silicosis and deaths from sandblasting. Cincinnati, Ohio: US Department of Health and Human Services, Public Health Service, CDC, 1992; DHHS publication no. (NIOSH)92-102.
- 6. CDC. Silicosis: cluster in sandblasters—Texas, and occupational surveillance for silicosis. MMWR 1990;39:433–6.
- 7. Rosenman KD, Reilly MJ, Rice C, Hertzberg V, Tseng C-Y, Anderson HA. Silicosis among foundry workers: implication for the need to revise the OSHA standard. Am J Epidemiol 1996;144: 890–900.
- 8. National Institute for Occupational Safety and Health. Alert: request for assistance in preventing silicosis and deaths in construction workers. Cincinnati, Ohio: US Department of Health and Human Services, Public Health Service, CDC, 1996; DHHS publication no. (NIOSH)96-112.
- 9. Valiante DJ, Rosenman KD. Does silicosis still occur? JAMA 1989;262:3003-6.

Notice to Readers

Publication of Surgeon General's Report on Smoking and Health

The Surgeon General's report, *Tobacco Use Among U.S. Racial/Ethnic Minority Groups*, was released on April 27, 1998. This report is the first to focus on tobacco use among four U.S. racial/ethnic minority groups: African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics.

The five major conclusions in the report are

- Cigarette smoking is a major cause of disease and death in each of the four population groups studied in this report. African Americans currently bear the greatest health burden. Differences in the magnitude of disease risk are directly related to differences in patterns of smoking.
- 2. Tobacco use varies within and among racial/ethnic minority groups; among adults, American Indians and Alaska Natives have the highest prevalence of tobacco use, and African American and Southeast Asian men also have a high

Notice to Readers — Continued

prevalence of smoking. Asian American and Hispanic women have the lowest prevalence.


- 3. Among adolescents, cigarette smoking prevalence increased in the 1990s among African Americans and Hispanics after several years of substantial decline among adolescents of all four racial/ethnic minority groups. This increase is particularly striking among African American youths, who had the greatest decline of the four groups during the 1970s and 1980s.
- 4. No single factor determines patterns of tobacco use among racial/ethnic minority groups; these patterns are the result of complex interactions of multiple factors, such as socioeconomic status, cultural characteristics, acculturation, stress, biological elements, targeted advertising, price of tobacco products, and varying capacities of communities to mount effective tobacco control initiatives.
- 5. Rigorous surveillance and prevention research are needed on the changing cultural, psychosocial, and environmental factors that influence tobacco use to improve our understanding of racial/ethnic smoking patterns and identify strategic tobacco control opportunities. The capacity of tobacco control efforts to keep pace with patterns of tobacco use and cessation depends on timely recognition of emerging prevalence and cessation patterns and the resulting development of appropriate community-based programs to address the factors involved.

Additional information about the report or a free copy of the executive summary is available from CDC's National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Mailstop K-50, 4770 Buford Highway, N.E., Atlanta, GA 30341-3724; telephone (770) 488-5705 (press 2); or World-Wide Web http://www.cdc.gov/tobacco. Faxed copies of the executive summary may be obtained from the Office on Smoking and Health's fax information system, telephone (800) 232-1311 and select "hot topics." Copies of the full report (stock no. 017-001-00527-4) are available for \$20 from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9328; telephone (202) 512-1800; fax (202) 512-1650. The executive summary of the report will be published as an *MMWR Recommendations and Reports*.

Reference

1. US Department of Health and Human Services. Tobacco use among U.S. racial/ethnic minority groups—African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics: a report of the Surgeon General. Atlanta, Georgia: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1998.

FIGURE I. Selected notifiable disease reports, comparison of provisional 4-week totals ending April 25, 1998, with historical data — United States



^{*}Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary — provisional cases of selected notifiable diseases, United States, cumulative, week ending April 25, 1998 (16th Week)

	Cum. 1998		Cum. 1998
Anthrax Brucellosis Cholera Congenital rubella syndrome Cryptosporidiosis* Diphtheria Encephalitis: California* eastern equine* St. Louis* western equine* Hansen Disease Hantavirus pulmonary syndrome* Hemolytic uremic syndrome, post-diarrheal* HIV infection, pediatric*	7 7 1 554 - - - - 41 - 5 72	Plague Poliomyelitis, paralytic [¶] Psittacosis Rabies, human Rocky Mountain spotted fever (RMSF) Streptococcal disease, invasive Group A Streptococcal toxic-shock syndrome* Syphilis, congenital** Tetanus Toxic-shock syndrome Trichinosis Typhoid fever Yellow fever	12 19 779 22 10 5 42 2 96

^{-:}no reported cases
*Not notifiable in all states.

† Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID). Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NOD).

Updated monthly to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP), last update March 29, 1998.

One suspected case of polio with onset in 1998 has also been reported to date.

**Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending April 25, 1998, and April 19, 1997 (16th Week)

						richia	-				
	All	DS	Chlai	nydia	coli O	157:H7 PHLIS [§]	Gono	rrhea	Hepa C/N/		
Reporting Area	Cum. 1998*	Cum. 1997	Cum. 1998	Cum. 1997	Cum. 1998	Cum. 1998	Cum. 1998	Cum. 1997	Cum. 1998	Cum. 1997	
UNITED STATES	12,103	17,701	153,032	138,573	243	99	90,877	84,365	1,382	833	
NEW ENGLAND	320	467	5,738	5,378	28	14	1,501	1,856	16	25	
Maine N.H.	8 13	18 4	284 283	287 237	1 5	2	14 29	14 47	-	2	
Vt.	8	16	113	126	-	-	8	16		1	
Mass. R.I.	98 32	217 43	2,714 766	2,244 653	12 3	10 1	656 102	719 166	16 -	20 2	
Conn.	161	169	1,578	1,831	7	1	692	894	-	-	
MID. ATLANTIC Upstate N.Y.	3,425 425	5,525 845	19,433 N	17,439 N	18 14	5 -	10,806 1,644	10,865 1,808	116 100	78 58	
N.Y. City	1,936	2,636	10,465	9,366	-	3	4,587	4,406	-	-	
N.J. Pa.	580 484	1,256 788	2,435 6,533	3,256 4,817	4 N	2	1,692 2,883	2,220 2,431	16	20	
E.N. CENTRAL	995	1,246	26,076	22,137	41	12	18,027	13,224	145	206	
Ohio Ind.	169 261	267 283	7,078 2,706	6,891 2,700	14 6	3 3	4,360 1,769	4,227 1,849	5 3	5 4	
IIId. III.	376	203 377	7,425	3,444	10	-	5,874	1,739	7	29	
Mich. Wis.	143 46	248 71	6,674 2,193	5,843 3,259	11 N	2 4	5,215 809	4,086 1,323	130	155 13	
W.N. CENTRAL	215	382	9,301	9,622	29	15	4,332	4,137	84	21	
Minn.	32	54	1,521	2,314	12	9	526	777	-	-	
lowa Mo.	11 101	51 209	1,268 3,751	1,509 3,492	2 5	- 5	391 2,463	380 2,197	8 73	11 2	
N. Dak.	3 7	3	290	295	1	1	29	22	-	2	
S. Dak. Nebr.	26	2 28	522 806	331 626	4	-	84 317	37 239	1	1	
Kans.	35	35	1,143	1,055	5	-	522	485	2	5	
S. ATLANTIC Del.	3,235 40	4,401 52	32,400 724	26,036 612	25	9 1	26,087 398	25,132 331	49	63	
Md.	334	564	2,541	2,054	9	4	2,740	3,897	3	6	
D.C. Va.	266 231	305 326	N 3,052	N 3,441	N	4	1,096 2,081	1,319 2,560	- 1	6	
W. Va.	30	23	825	1,000	Ŋ	-	223	303	3 7	3	
N.C. S.C.	217 187	218 237	6,929 5,875	5,232 3,720	7 1	-	5,806 3,639	4,792 3,243	-	18 14	
Ga. Fla.	371 1,559	533 2,143	7,328 5,126	2,406 7,571	2 6	-	6,148 3,956	3,425 5,262	8 27	16	
E.S. CENTRAL	444	542	11,535	10,162	17	6	11,025	10,389	37	106	
Ky.	65	48	1,883	1,984	3	-	1,067	1,358	4	5	
Tenn. Ala.	144 119	246 152	3,770 3,151	3,772 2,479	10 4	6	3,192 3,993	3,233 3,405	30 3	61 5	
Miss.	116	96	2,731	1,927	-	-	2,773	2,393	-	35	
W.S. CENTRAL Ark.	1,370 52	1,941 83	19,980 1,071	15,267 777	12 1	1	11,662 1,092	10,453 1,330	431	76 1	
La.	212	308	3,144	2,161	-	-	2,702	2,092	1	55	
Okla. Tex.	71 1,035	116 1,434	3,023 12,742	2,320 10,009	1 10	1 -	1,624 6,244	1,494 5,537	430	4 16	
MOUNTAIN	389	551	5,612	7,655	21	12	2,079	2,382	254	101	
Mont. Idaho	10 8	12 17	330 564	276 468	1 2	-	17 48	14 33	4 77	4 15	
Wyo.	1	11	218	151	-	-	11	18	111	36	
Colo. N. Mex.	65 55	170 35	- 1,117	1,252 1,148	2 5	1 4	755 201	631 418	11 24	14 17	
Ariz.	128	123	2,676	2,966	N	3	908	958	1	10 2	
Utah Nev.	35 87	39 144	454 253	467 927	7 4	1 3	47 92	53 257	14 12	2 3	
PACIFIC	1,710	2,646	22,957	24,877	52	25	5,358	5,927	250	157	
Wash. Oreg.	137 40	238 97	3,372 1,711	2,867 1,451	14 13	11 8	580 247	649 216	6 2	8 1	
Calif.	1,499	2,269	16,671	19,635	25	3	4,316	4,780	207	96	
Alaska Hawaii	11 23	18 24	624 579	428 496	- N	3	96 119	145 137	1 34	- 52	
Guam	-	2	8	139	N	_	2	16	-	-	
P.R.	460	419	U	U N	- N	U U	121	177	-	29	
V.I. Amer. Samoa	13 -	16 -	N -	-	N	U	-	-	-	-	
C.N.M.I.	-	-	N	N	N	U	7	11	-	2	

N: Not notifiable

U: Unavailable

-: no reported cases

C.N.M.I.: Commonwealth of Northern Mariana Islands

^{*}Updated monthly to the Division of HIV/AIDS Prevention-Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention,

last update March 29, 1998.

†National Electronic Telecommunications System for Surveillance.

§Public Health Laboratory Information System.

TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States, weeks ending April 25, 1998, and April 19, 1997 (16th Week)

	Legion	Lyme egionellosis Disease		Mai	aria	Syp (Primary &		Tubero	culosis	Rabies, Animal	
Reporting Area	Cum. 1998	Cum. 1997	Cum. 1998	Cum. 1997	Cum. 1998	Cum. 1997	Cum. 1998	Cum. 1997	Cum. 1998*	Cum. 1997	Cum. 1998
UNITED STATES	301	253	1,076	924	309	381	2,079	2,680	1,656	4,573	2,110
NEW ENGLAND	17	21	197	175	13	15	20	47	70	104	418
Maine N.H.	1 2	1 3	5	2 4	1 2	2	1 -	-	U 2	11 1	71 33
Vt. Mass.	1 3	3 9	2 52	2 35	10	1 11	- 17	23	1 53	- 50	22 122
R.I. Conn.	4	1	19 119	29 103	-	1	2	24	14 U	7 35	29 141
MID. ATLANTIC	66	42	683	611	- 87	98	76	128	147	808	477
Upstate N.Y. N.Y. City	22 6	9 1	385	71 47	25 39	15 55	4 16	15 21	U U	93 452	325 U
N.J.	3	5	52	152	14	18	18	64	147	174	61
Pa. E.N. CENTRAL	35 102	27 106	246 22	341 10	9 21	10 39	38 298	28 239	U 83	89 456	91 15
Ohio	47	52	21	5	2	3	54	79	5	104	15
Ind. III.	16 9	12 4	1 -	4 1	1 5	4 16	54 120	54 19	U 78	40 214	-
Mich. Wis.	22 8	28 10	Ū	Ū	12 1	13 3	52 18	35 52	U U	70 28	-
W.N. CENTRAL	24	15	9	9	16	9	52	62	55	129	194
Minn. Iowa	3 2	2	3 5	7	8 2	4 2	-	16 3	U U	34 15	30 41
Mo. N. Dak.	8	2 1	-	1	4	2	42	29	50 U	49 2	12 42
S. Dak.	- 8	1 5	-	-	-	-	-	-	4	2	33
Nebr. Kans.	3	4	1	1 -	2	1 -	4 6	14	1 U	4 23	36
S. ATLANTIC	44	31	115	85 17	76	76	860	1,075	294	785	711
Del. Md.	6 8	3 10	93	17 57	1 26	2 25	7 198	8 305	75	8 78	17 1 6 8
D.C. Va.	3 4	1 4	4 4	4	4 9	5 18	30 66	41 94	33 53	23 86	200
W. Va. N.C.	N 4	N 5	4 1	2	- 7	- 5	244	2 220	19 114	15 109	31 136
S.C.	4	2	2	1	, 13	4	96	119 192	Ü	80	41
Ga. Fla.	15	6	7	3	16	11 6	148 71	94	Ü	130 256	45 73
E.S. CENTRAL	6 3	8	13 2	17 1	8	9 3	364 41	582 52	- U	352 46	71 13
Ky. Tenn.	3	3	6	3	5	2	183	235	Ū	128	39
Ala. Miss.	-	2 3	5 -	2 11	3 -	1 3	79 61	151 144	U U	118 60	19 -
W.S. CENTRAL	3	1	3	2	9	6	235	380	33	679	60
Ark. La.	-	-	2	1	3	1 3	46 87	53 133	33	59 39	1 -
Okla. Tex.	3	1 -	1	1	1 5	2	13 89	35 159	U U	49 532	59 -
MOUNTAIN	17	16	1	1	16	21	62	52	74	122	45
Mont. Idaho	1 -	1 1	-	-	1	2	-	-	2 3	2 4	15 -
Wyo. Colo.	1 4	1 4	-	-	6	1 10	4	2	1 U	1 26	29
N. Mex. Ariz.	2	4	-	-	6 2	2	54	43	7 43	6 51	- 1
Utah	6	4	-	-	1	-	2	1	18	4	-
Nev. PACIFIC	1 22	1 13	1 33	1 14	63	3 108	2 112	6 115	U 900	28 1,138	- 119
Wash.	2	3	1	-	3	3 7	6	5	U	87	-
Oreg. Calif.	20	9	1 31	7 7	6 53	96	2 104	3 106	U 840	41 914	109
Alaska Hawaii	-	1	-	-	1	2	-	1	11 49	29 67	10 -
Guam	-	-	-	-	-	-	-	2	-	13	
P.R. V.I.	-	-	-	-	-	3	69 -	64	-	-	23
Amer. Samoa C.N.M.I.	-	-	-	-	-	-	- 1	4	8	-	-

N: Not notifiable U: Unavailable -: no reported cases

^{*}Additional information about areas displaying "U" for cumulative 1998 Tuberculosis cases can be found in Notice to Readers, MMWR Vol. 47, No. 2, p. 39.

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending April 25, 1998, and April 19, 1997 (16th Week)

	H. influ	ienzae,	Hepatitis (Viral), by type					K,	Meas	les (Rube	ola)	
		sive	A			3	Indi	genous		ported [†]		tal
Reporting Area	Cum. 1998*	Cum. 1997	Cum. 1998	Cum. 1997	Cum. 1998	Cum. 1997	1998	Cum. 1998	1998	Cum. 1998	Cum. 1998	Cum. 1997
UNITED STATES	356	371	6,197	8,166	2,197	2,669	-	3	1	10	13	28
NEW ENGLAND	20	21	94	198	20	56	-	-	-	1	1	-
Maine N.H.	2 1	2 3	10 6	18 9	- 5	3 5	-	-	-	-	-	-
Vt.	2	-	7	5	-	1	-	-	-	-	-	-
Mass. R.I.	13 2	14 1	21 7	107 11	9 6	29 6	-	-	-	1 -	1 -	-
Conn.	-	1	43	48	-	12	-	-	-	-	-	-
MID. ATLANTIC Upstate N.Y.	49 18	46 1	391 115	739 73	283 101	416 62	-	-	-	1	1	10 3
N.Y. City	10	18	99	364	82	176	-	-	-	-	-	5
N.J. Pa.	19 2	17 10	82 95	121 181	100	84 94	-	-	-	1	1	1 1
E.N. CENTRAL	51	57	756	1,051	225	530	_	-	_	2	2	6
Ohio	25	28 4	117	144	24 20	32	- U	-	- U	-	- 1	-
Ind. III.	9 16	16	66 106	90 270	34	34 103	-	-	-	1 -	1 -	5
Mich. Wis.	- 1	9	418 49	478 69	141 6	164 197	-	-	-	1	1	1
W.N. CENTRAL	27	19	564	577	104	175	_	_	_	_	_	2
Minn.	16	10	28	35	11	5	-	-	-	-	-	1
lowa Mo.	1 6	2 3	263 213	77 331	15 60	11 138	-	-	-	-	-	1
N. Dak. S. Dak.	-	2	2 3	6 6	1 1	1	-	-	-	-	-	-
Nebr.	-	1	13	21	4	7	Ū	-	Ū	-	-	-
Kans.	4	1	42	101	12	13	-	-	-	-	-	-
S. ATLANTIC Del.	79 -	73 -	557 1	437 10	328	313 2	-	1 -	1 1	5 1	6 1	1 -
Md.	19	28	122	109	44 5	56	-	-	-	1	1	1
D.C. Va.	11	5	21 86	11 54	30	18 35	-	-	-	2	2	-
W. Va. N.C.	2 10	2 12	32	5 61	2 69	6 72	-	-	-	-	-	-
S.C.	1	3	11	36	-	32	-	-	-	-	-	-
Ga. Fla.	18 18	16 7	112 172	41 110	59 119	15 77	-	- 1	-	1 -	1 1	-
E.S. CENTRAL	19	21	117	210	145	197	-	-	-	-	-	1
Ky. Tenn.	2 12	4 12	2 83	27 118	9 111	11 124	-	-	-	-	-	-
Ala.	5	5	32	37	25	28	-	-	-	-	-	1
Miss.	-	-	-	28	-	34	U	-	U	-	-	-
W.S. CENTRAL Ark.	22	17 1	1,026 15	1,209 80	333 21	170 17	-	-	-	-	-	2
La. Okla.	11 10	1 13	12 161	64 529	8 16	39 9	-	-	-	-	-	-
Tex.	10	2	838	536	288	105	-	-	-	-	-	2
MOUNTAIN	54	41	1,032	1,288	263	272	-	-	-	-	-	-
Mont. Idaho	-	-	10 77	39 58	2 13	2 8	-	-	-	-	-	-
Wyo. Colo.	- 10	1 5	20 80	14 150	13 7 35	6 55	-	-	-	-	-	-
N. Mex.	3	2	59	81	103	94	-	-	-	-	-	-
Ariz. Utah	31 4	12 3	661 69	588 250	62 21	58 31	-	-	-	-	-	-
Nev.	6	18	56	108	20	18	-	-	-	-	-	-
PACIFIC Week	35	76 1	1,660	2,457	496	540	-	2	-	1	3	6
Wash. Oreg.	1 21	1 14	285 125	172 126	38 40	17 37	-	-	-	-	-	-
Calif. Alaska	10 1	58 1	1,229 3	2,092 15	412 2	472 10	-	2	-	1	3	3
Hawaii	2	2	18	52	4	4	-	-	-	-	-	3
Guam	-	-	-	-	-	1	U	-	U	-	-	-
P.R. V.I.	1 -	-	10	113 -	188 -	405 -	Ū	-	Ū	-	-	-
Amer. Samoa	-	- 4	-	- 1	- 7	- 19	Ü	-	Ü	-	-	- 1
C.N.M.I.		4	-	ı	1	19	U	-	U	-	-	ı

N: Not notifiable

U: Unavailable

^{-:} no reported cases

 $^{^*\}hspace{-0.5em}.$ Of 85 cases among children aged <5 years, serotype was reported for 42 and of those, 22 were type b.

[†]For imported measles, cases include only those resulting from importation from other countries.

TABLE III. (Cont'd.) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending April 25, 1998, and April 19, 1997 (16th Week)

	Mening Dise			Mumps			Pertussis		Rubella			
Reporting Area	Cum. 1998	Cum. 1997	1998	Cum. 1998	Cum. 1997	1998	Cum. 1998	Cum. 1997	1998	Cum. 1998	Cum. 1997	
UNITED STATES	986	1,306	12	149	186	46	1,144	1,611	7	157	20	
NEW ENGLAND	52	82	-	-	6	5	201	416	1	24	-	
Maine N.H.	4 1	8 7	-	-	-	- 1	5 19	6 45	-	-	-	
Vt.	1	2	-	-	-	-	22	142	-	-	-	
Mass. R.I.	24 3	48 4	-	-	1 4	4	150 -	207 11	-	2	-	
Conn.	19	13	-	-	1	-	5	5	1	22	-	
MID. ATLANTIC Upstate N.Y.	106 28	133 29	-	6 3	25 4	7 7	145 88	145 55	-	79 79	7 1	
N.Y. City	10	21	-	-	1	-	-	34	-	-	6	
N.J. Pa.	29 39	27 56	-	3	3 17	-	- 57	9 47	-	-	-	
E.N. CENTRAL	137	187	2	22	24	5	129	177	-	-	3	
Ohio Ind.	55 25	68 19	1 U	11 2	8 4	5 U	49 40	55 13	Ū	-	-	
III.	28	63	1	1	7	-	7	24	-	-	-	
Mich. Wis.	14 15	17 20	-	8 -	4 1	-	16 17	25 60	-	-	3	
W.N. CENTRAL	84	97	-	16	7	-	84	94	-	1	-	
Minn. Iowa	16 11	8 22	-	9 5	3 3	-	55 13	59 7	-	-	-	
Mo.	33	50	-	1	-	-	9	12	-	1	-	
N. Dak. S. Dak.	- 5	3	-	1 -	-	-	4	2 1	-	-	-	
Nebr. Kans.	4 15	4 10	U	-	1	U	3	2 11	U	-	-	
S. ATLANTIC	183	223	- 7	- 27	23	6	90	144	2	- 5	1	
Del.	1	4	-	-	-	-	-	-	-	-	-	
Md. D.C.	16 -	26 5	-	2	4	- 1	17 1	61 2	-	-	-	
Va. W. Va.	17 4	19 8	-	4	2	-	6 1	17 3	-	-	1	
N.C.	24	39	-	6	6	2	40	28	2	3	-	
S.C. Ga.	27 40	33 37	-	3	1 2	2	9	7 2	-	1 -	-	
Fla.	54	52	7	12	8	1	16	24	-	1	-	
E.S. CENTRAL Ky.	70 8	92 22	-	-	11	1 -	26 9	35 10	-	-	-	
Tenn.	32	28	-	-	3	1	7	10	-	-	-	
Ala. Miss.	30	27 15	Ū	-	4 4	Ū	10 -	9 6	Ū	-	-	
W.S. CENTRAL	72	108	1	22	22	1	54	33	3	36	1	
Ark. La.	13 20	21 22	- 1	1	6	1 -	7	2 7	-	-	-	
Okla. Tex.	21 18	13 52	-	21	16	-	6 41	5 19	3	- 36	- 1	
MOUNTAIN	65	83	-	13	8	20	264	336	-	50 5	-	
Mont.	2	4	-	-	-	-	1	2	-	-	-	
Idaho Wyo.	3 3	5 -	-	1	2	9	124 7	212 3	-	-	-	
Colo. N. Mex.	14 12	25 14	- N	2 N	2 N	7 1	41 49	93 12	-	- 1	-	
Ariz.	22	16	-	4	-	-	22	9	-	1	-	
Utah Nev.	6 3	10 9	-	1 5	2 2	1 2	13 7	1 4	-	2 1	-	
PACIFIC	217	301	2	43	60	1	151	231	1	7	8	
Wash. Oreg.	25 42	33 66	- N	4 N	4 N	1 -	81 8	104 8	1	5	-	
Calif.	146	199	2	27	43	-	58	113	-	1	4	
Alaska Hawaii	1 3	1 2	-	2 10	3 10	-	4	2 4	-	- 1	4	
Guam	-	1	U	-	1	U	-	-	U	-	-	
P.R. V.I.	1	6	- U	2	4	Ū	2	-	Ū	-	-	
Amer. Samoa	-	-	U	-	-	U	-	-	U	-	-	
C.N.M.I.	-	-	U	-	-	U	-	-	U	-	-	

N: Not notifiable

U: Unavailable

-: no reported cases

TABLE IV. Deaths in 122 U.S. cities,* week ending April 25, 1998 (16th Week)

Reporting Area NEW ENGLAND	All Ages			_	ears)		P&I [†]		All Causes, By Age (Years)						
NEW ENGLAND		>65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	>65	45-64	25-44	1-24	<1	P&I [†] Total
Boston, Mass. Bridgeport, Conn. Cambridge, Mass. Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Mass. New Haven, Conn. Providence, R.I. Somerville, Mass. Springfield, Mass. Waterbury, Conn.	520 123 36 7 37 51 26 8 16 29 50 8 40 26	367 74 27 6 30 32 18 5 15 19 41 6 30	8 4 12 3 2 1 7 6 1 5	34 13 1 1 2 4 3 1 1 2 1 2	9 3 - - 2 1 - - 1	12 3 - 1 1 1 1 - 3	37 13 3 2 1 1 -	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla. Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, Fla. Tampa, Fla. Washington, D.C. Wilmington, Del.	1,466 U 207 80 134 110 51 57 60 54 216 486 11	991 U 151 58 92 68 30 43 41 156 303 6	285 U 40 14 25 27 13 6 10 6 41 103	127 U 5 8 12 13 4 6 4 4 11 55 5	38 U 9 - 1 1 4 1 - 4 18	24 U 2 - 4 1 - - 3 3 4 7	87 U 9 11 4 2 6 6 5 26 18
Worcester, Mass.	63 2,174 48 15 U 25 19 51 38	1,522 38 10 U 13 14 45 20 791 16 282 33 28 87 14 27 66 18 20 0	12 423 5 3 U 5 5 5 12 250 0 6 70 12 5 11 5 11 13	3 162 3 2 U 3 - 16 102 U 2 31 2 1 3 - -	35 1 	1 32 1 - - - - 11 U 4 6 5 - - - - - - - - - - - - - - - - - -	9 111 6 · U 3 · 3 39 U · 26 3 3 3 14 · 1 13 · · · U	E.S. CENTRAL Birmingham, Ala. Chattanooga, Tenn. Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Ala. Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La. Corpus Christi, Tex. Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La. San Antonio, Tex. Shreveport, La. Tulsa, Okla.	83 98 237 65 59 169 1,529 82 27	678 147 62 53 67 157 49 31 112 967 63 17 39 115 36 81 253 61 50 109 84	225 54 21 18 54 10 14 33 322 12 3 14 34 34 34 27 99 15 24 31 24 24	81 18 9 4 9 20 25 14 156 5 4 33 7 12 37 5 20 16 4 8	32 9 5 1 1 4 5 7 39 1 1 10 - 3 13 1 2 4 2 1	22 7 3 5 4 3 4 1 1 7 5 10 9 1 1 5 3 3	87 17 18 9 28 5 6 97 3 2 5 1 15 33 - 11 9 18
	2,172 43 38 416 105 2125 220 58 229 66 179 35 117 44 44 52 118 63 819 109 27 33 86 32 189 71 112	1,4800 299 254 699 81 148 95 134 49 51 113 25 85 33 34 40 93 53 58 68 85 19 20 61 28 134 56 66	395 9 5 71 23 26 41 23 46 3 20 6 11 38 8 22 9 4 7 18 5 14 3 7 14 2 3 7 14 3 7 14 14 15 16 16 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	155 3 2 37 4 12 16 3 26 5 5 3 5 5 1 2 5 2 3 44 6 6 5 5 4 1 10 2 7 2	61 11 12 41 13 39 11 52 11 91 11 11 72 52	788 1 1 399 55 55 1 1 5 - 2 4 4 1 1 1 - 3 3 - 2 2 1 1 - 4 4 4 4 4 4 4 4 4	144 3 321 15 23 14 6 2 1 4 11 4 4 1 7 2 47 15 2 1 5 1 14 3 6	MOUNTAIN Albuquerque, N.M. Boise, Idaho Colo. Springs, Colo Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, Utah Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawaii Long Beach, Calif. Los Angeles, Calif. Portland, Oreg. Sacramento, Calif. San Diego, Calif. San Francisco, Calif. San Jose, Calif. Santa Cruz, Calif. Seattle, Wash. Spokane, Wash. Tacoma, Wash.	U 180 23 206 30 117 125 1,954 23 96 36 83 58 613 U 111 197 153	595 49 39 41 124 132 25 788 81,409 16 65 30 63 42 448 150 109 30 94 47 56 8,595	176 16 9 13 U 42 3 45 1 27 20 337 5 18 5 14 7 111 U 20 27 27 28 28 3 20 9 15	65 5 4 2 U 12 1 14 4 8 15 139 4 2 6 4 4 4 6 7 18 13 11 11 11 11 11 11 11 11 11 11 11 11	19 1 2 1 U 1 9 - 3 2 37 1 6 - 2 1 5 U - 5 4 1 1 2 - 8 1 1 2 - 8 1 1 2 - 8 1 1 2 - 8 1 1 2 - 8 1 1 2 - 8 1 1 1 2 - 8 1 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2	13 1 4 - U 1 1 - 6 - 1 32 1 3 1 1 2 2 5 5 U 1 8 8 1 1 2 2 2 - 1 1 2 2 2 279	63 4 6 1 10 16 2 12 3 11 8 18 5 2 7 3 7 6 3 5 3 1 1 1 1 6 2 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8

U: Unavailable -: no reported cases

*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

†Pneumonia and influenza.

Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

Total includes unknown ages.

Notice to Readers

National Melanoma/Skin Cancer Detection and Prevention Month — May 1998

May has been designated National Melanoma/Skin Cancer Detection and Prevention Month by the American Academy of Dermatology (AAD). In 1998, approximately 1 million new cases of basal cell and squamous cell carcinomas will be detected, and approximately 41,600 new cases of malignant melanoma will be diagnosed (1). In addition, in 1998, an estimated 9200 persons will die from skin cancer. This month is dedicated to increasing the awareness of the importance of skin cancer prevention, early detection, and treatment.

Overexposure to ultraviolet (UV) rays is the most important behavioral risk factor for skin cancer. Measures to prevent skin cancer include 1) reducing direct exposure to the sun, especially during midday hours (i.e., 10 a.m.–4 p.m.) when the sun's rays are the strongest; 2) wearing protective clothing (e.g., broad-brimmed hat, long-sleeved shirt, long pants, and sun glasses); and 3) using sunscreen with a sun protection factor of at least 15 to protect against UV A and B rays (1). Persons should also avoid artificial sources of UV light, such as tanning beds and sun lamps (2).

CDC's National Skin Cancer Prevention Education Program, in collaboration with AAD, the American Cancer Society, the U.S. Environmental Protection Agency, the National Weather Service, state health departments, universities, and other public and private organizations, has focused on increasing public awareness about skin cancer risk factors and appropriate sun protection behaviors. Program efforts include media campaigns and health education efforts among target groups, prevention education for nurses, evaluation of a UV index and UV index worksite demonstration project, development of school and community health guidelines for skin cancer prevention/sun protection, and formation of a national council for skin cancer prevention.

Additional information about skin cancer is available from the National Cancer Institute, telephone (800) 422-6237, and from the American Cancer Society, telephone (800) 227-2345. Information about AAD's program is available from the World-Wide Web http://www.aad.org. Information about CDC's program is available at http://www.cdc.gov/nccdphp/dcpc/nscpep.

References

- American Cancer Society. Cancer facts and figures, January 1998. Atlanta, Georgia: American Cancer Society, 1998.
- Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives—full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service, 1990; DHHS publication no. (PHS)91-50212.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/ or from CDC's file transfer protocol server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the MMWR Series, including material to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Acting Director, Centers for Disease Control and Prevention Claire V. Broome, M.D.

Acting Deputy Director, Centers for Disease Control and Prevention Stephen B. Thacker, M.D., M.Sc.

Acting Director,
Epidemiology Program Office
Barbara R. Holloway, M.P.H.
Acting Editor, MMWR Series
Andrew G. Dean, M.D., M.P.H.
Managing Editor, MMWR (weekly)
Karen L. Foster, M.A.

Writers-Editors, MMWR (weekly)
David C. Johnson
Teresa F. Rutledge
Caran R. Wilbanks
Desktop Publishing and
Graphics Support
Morie M. Higgins
Peter M. Jenkins

☆U.S. Government Printing Office: 1998-633-228/67074 Region IV